FR2791894B1 - Utilisation d'interferon beta dans le traitement de la tumeur d'ewing - Google Patents

Utilisation d'interferon beta dans le traitement de la tumeur d'ewing

Info

Publication number
FR2791894B1
FR2791894B1 FR9904480A FR9904480A FR2791894B1 FR 2791894 B1 FR2791894 B1 FR 2791894B1 FR 9904480 A FR9904480 A FR 9904480A FR 9904480 A FR9904480 A FR 9904480A FR 2791894 B1 FR2791894 B1 FR 2791894B1
Authority
FR
France
Prior art keywords
treatment
ewing
interferon
beta
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9904480A
Other languages
English (en)
Other versions
FR2791894A1 (fr
Inventor
Josiane Sanceau
Jeanne Wietzerbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9904480A priority Critical patent/FR2791894B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to US09/958,274 priority patent/US6749846B1/en
Priority to AU49189/00A priority patent/AU4918900A/en
Priority to ES00931158T priority patent/ES2234605T3/es
Priority to AT00931158T priority patent/ATE280584T1/de
Priority to CA2369427A priority patent/CA2369427C/fr
Priority to EP00931158A priority patent/EP1165117B1/fr
Priority to PCT/EP2000/004171 priority patent/WO2000061172A1/fr
Priority to DE60015306T priority patent/DE60015306T2/de
Publication of FR2791894A1 publication Critical patent/FR2791894A1/fr
Application granted granted Critical
Publication of FR2791894B1 publication Critical patent/FR2791894B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR9904480A 1999-04-09 1999-04-09 Utilisation d'interferon beta dans le traitement de la tumeur d'ewing Expired - Fee Related FR2791894B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9904480A FR2791894B1 (fr) 1999-04-09 1999-04-09 Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
AU49189/00A AU4918900A (en) 1999-04-09 2000-04-10 Interferon-beta use in the treatment of ewing's family of tumors
ES00931158T ES2234605T3 (es) 1999-04-09 2000-04-10 Utilizacion de beta-interferon en la fabricacion de un medicamento destinado al tratamiento del sarcoma de ewing y eoe.
AT00931158T ATE280584T1 (de) 1999-04-09 2000-04-10 Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
US09/958,274 US6749846B1 (en) 1999-04-09 2000-04-10 Interferon-beta use in the treatment of ewing's family of tumors
CA2369427A CA2369427C (fr) 1999-04-09 2000-04-10 Utilisation d'interferon-beta dans le traitement de la famille de tumeurs d'ewing
EP00931158A EP1165117B1 (fr) 1999-04-09 2000-04-10 Utilisation d'interferon-beta pour la preparation d'un medicament pour le traitement du sarcome d'ewing et de eoe
PCT/EP2000/004171 WO2000061172A1 (fr) 1999-04-09 2000-04-10 Utilisation d'interferon-beta dans le traitement de la famille de tumeurs d'ewing
DE60015306T DE60015306T2 (de) 1999-04-09 2000-04-10 Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904480A FR2791894B1 (fr) 1999-04-09 1999-04-09 Utilisation d'interferon beta dans le traitement de la tumeur d'ewing

Publications (2)

Publication Number Publication Date
FR2791894A1 FR2791894A1 (fr) 2000-10-13
FR2791894B1 true FR2791894B1 (fr) 2001-07-13

Family

ID=9544241

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9904480A Expired - Fee Related FR2791894B1 (fr) 1999-04-09 1999-04-09 Utilisation d'interferon beta dans le traitement de la tumeur d'ewing

Country Status (9)

Country Link
US (1) US6749846B1 (fr)
EP (1) EP1165117B1 (fr)
AT (1) ATE280584T1 (fr)
AU (1) AU4918900A (fr)
CA (1) CA2369427C (fr)
DE (1) DE60015306T2 (fr)
ES (1) ES2234605T3 (fr)
FR (1) FR2791894B1 (fr)
WO (1) WO2000061172A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030130A0 (fi) * 2003-01-29 2003-01-29 Licentia Oy Seulontamenetelmä

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
CA2200879A1 (fr) * 1995-07-25 1997-02-13 Nobutaka Ida Remede contre les maladies osseuses

Also Published As

Publication number Publication date
DE60015306D1 (de) 2004-12-02
AU4918900A (en) 2000-11-14
FR2791894A1 (fr) 2000-10-13
WO2000061172A1 (fr) 2000-10-19
CA2369427A1 (fr) 2000-10-19
EP1165117B1 (fr) 2004-10-27
ES2234605T3 (es) 2005-07-01
ATE280584T1 (de) 2004-11-15
US6749846B1 (en) 2004-06-15
EP1165117A1 (fr) 2002-01-02
CA2369427C (fr) 2011-01-04
DE60015306T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
CO4940414A1 (es) Terapia de interferones polietilenglicol modificados
DE69914463D1 (en) Therapeutische chemokine rezeptor antagonisten
KR920700200A (ko) 19-노르-비타민 d 화합물
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
ATE268183T1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
TW265265B (fr)
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
PT1039900E (pt) Agentes terapeuticos
AU9157901A (en) Methods of treating inflammatory and immune reactions and compositions therefor
IL130785A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
CA2361081A1 (fr) Traitement de la sclerose en plaques a la chaperonine 10 et au .beta.-interferon
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
RU2003100517A (ru) Новый интерферон для лечения рассеянного склероза
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
ES2183977T3 (es) Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
SE8903117D0 (sv) Laekemedel omfattande antamanid
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091231